BLFS icon

BioLife Solutions

22.53 USD
-0.31
1.36%
Updated Apr 1, 3:50 PM EDT
1 day
-1.36%
5 days
-12.57%
1 month
-8.08%
3 months
-13.94%
6 months
-6.67%
Year to date
-13.94%
1 year
25.87%
5 years
144.89%
10 years
1,402.00%
 

About: BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Employees: 159

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

7% more capital invested

Capital invested by funds: $1.14B [Q3] → $1.21B (+$76.1M) [Q4]

2.35% more ownership

Funds ownership: 98.53% [Q3] → 100.88% (+2.35%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

7% less funds holding

Funds holding: 193 [Q3] → 179 (-14) [Q4]

33% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 33

34% less call options, than puts

Call options by funds: $122K | Put options by funds: $184K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$30
33%
upside
Avg. target
$31
35%
upside
High target
$31
38%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
38% 1-year accuracy
63 / 167 met price target
33%upside
$30
Buy
Maintained
6 Mar 2025
Northland Capital Markets
Carl Byrnes
67% 1-year accuracy
4 / 6 met price target
38%upside
$31
Outperform
Maintained
8 Jan 2025

Financial journalist opinion

Based on 6 articles about BLFS published over the past 30 days

Positive
Zacks Investment Research
1 week ago
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being.
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
Neutral
PRNewsWire
2 weeks ago
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven.
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
Positive
Zacks Investment Research
3 weeks ago
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW.
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment
Neutral
Seeking Alpha
4 weeks ago
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
4 weeks ago
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.30 per share a year ago.
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
Neutral
PRNewsWire
4 weeks ago
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results
Cell Processing revenue up 7%  sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12%  over prior year to $73.5 million GAAP gross margin of 60%  and non-GAAP adjusted gross margin of 63%  for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18%  of total revenue for the fourth quarter Expects 2025  Cell Processing revenue of $86.5 to $89.0 million, up 18%  to 21%  over 2024 and total revenue of $95.5 to $99.0 million, up 16%  to 20%  over 2024 Conference call begins at 8:00 a.m. Eastern time today  BOTHELL, Wash.
BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
PRNewsWire
1 month ago
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market.
BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025
Positive
Zacks Investment Research
1 month ago
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why
BioLife Solutions (BLFS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Recent Price Trend in BioLife Solutions (BLFS) is Your Friend, Here's Why
Positive
Zacks Investment Research
2 months ago
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?
BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?
Positive
Zacks Investment Research
2 months ago
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
Charts implemented using Lightweight Charts™